Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Mar 24, 2017 11:15am

175 Views

Post# 26025900

RE:RE:RE:MOA apabetalone (rvx-208)

BigDolphin asked "Why doesn't it reflect in our share price?", but also recently stated "You're a broken record....You've been repeating the same XXXX for years.....We all know the same thing."

Since you've "been in it for so long," you've heard the reasoning from myself and many other posters before (and very recently). To avoid being a broken record and repeating the things that we all know, you can just go back and look at posts in the recent past.

BDAZ

Bullboard Posts

Visionstate set to leverage success in the U.S. market